NCT05630183Phase 2Completed

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01-05Actual

Enrollment · participants81Actual

Source updated2026-06-11Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-11 · 3 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~5 Dec 2025~~

+ After

5 Jan 2026

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Posted 2025-11-13 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Progression-free Survival as Assessed by ~~Independent Central Review Committee (IRC)~~

+ After

Measure: Progression-free Survival as Assessed by Investigator

Check registry source

Study details

Conditions studied

Metastatic Pancreatic Ductal Adenocarcinoma

Treatments or interventions studied

BotensilimabDrugAlso known as AGEN1181
GemcitabineDrug
Nab-paclitaxelDrug

Primary outcomes · main study measures

measure: Progression-free Survival as Assessed by Investigator; description: Progression-free survival will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression, assessed by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), or death, whichever occurs first.; timeFrame: Up to 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history